CA2902342C - Neoseptins: small molecule adjuvants - Google Patents

Neoseptins: small molecule adjuvants Download PDF

Info

Publication number
CA2902342C
CA2902342C CA2902342A CA2902342A CA2902342C CA 2902342 C CA2902342 C CA 2902342C CA 2902342 A CA2902342 A CA 2902342A CA 2902342 A CA2902342 A CA 2902342A CA 2902342 C CA2902342 C CA 2902342C
Authority
CA
Canada
Prior art keywords
mmol
equiv
et0ac
rule
substitute sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2902342A
Other languages
English (en)
French (fr)
Other versions
CA2902342A1 (en
Inventor
Bruce Beutler
Dale L. Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
The University of Texas System
Original Assignee
Scripps Research Institute
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, The University of Texas System filed Critical Scripps Research Institute
Publication of CA2902342A1 publication Critical patent/CA2902342A1/en
Application granted granted Critical
Publication of CA2902342C publication Critical patent/CA2902342C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2902342A 2013-02-25 2014-02-25 Neoseptins: small molecule adjuvants Expired - Fee Related CA2902342C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768712P 2013-02-25 2013-02-25
US61/768,712 2013-02-25
PCT/US2014/018380 WO2014131023A1 (en) 2013-02-25 2014-02-25 Neoseptins: small molecule adjuvants

Publications (2)

Publication Number Publication Date
CA2902342A1 CA2902342A1 (en) 2014-08-28
CA2902342C true CA2902342C (en) 2017-10-17

Family

ID=51391916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902342A Expired - Fee Related CA2902342C (en) 2013-02-25 2014-02-25 Neoseptins: small molecule adjuvants

Country Status (7)

Country Link
US (1) US9649373B2 (enExample)
EP (1) EP2958889B1 (enExample)
JP (1) JP6356160B2 (enExample)
CN (1) CN105339346B (enExample)
AU (1) AU2014218598B2 (enExample)
CA (1) CA2902342C (enExample)
WO (1) WO2014131023A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
WO2016145092A1 (en) 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
WO2016161342A2 (en) * 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
US20180169064A1 (en) 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
WO2017083823A1 (en) * 2015-11-13 2017-05-18 Brandeis University Mtor inhibitors and methods of use thereof
BR112018077397A2 (pt) * 2016-06-29 2019-10-01 The Scripps Research Institute diprovocims: uma classe de agonistas de tlr
KR102775718B1 (ko) 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031083A (en) 1975-10-24 1977-06-21 Yeda Research And Development Co., Ltd. Cephalosporin antibiotics
US4045438A (en) 1975-10-24 1977-08-30 Yeda Research And Development Co. Ltd. Cephalosporin antibiotics
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
EP2292628A3 (en) * 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
JP2009542689A (ja) * 2006-07-07 2009-12-03 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 選択的カスパーゼ阻害剤
EP2510946B1 (en) * 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
SI2268618T1 (sl) * 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト

Also Published As

Publication number Publication date
EP2958889B1 (en) 2017-03-22
JP6356160B2 (ja) 2018-07-11
CN105339346A (zh) 2016-02-17
CN105339346B (zh) 2017-03-08
EP2958889A4 (en) 2016-07-27
US9649373B2 (en) 2017-05-16
WO2014131023A1 (en) 2014-08-28
JP2016513128A (ja) 2016-05-12
US20160000907A1 (en) 2016-01-07
AU2014218598A1 (en) 2015-09-10
AU2014218598B2 (en) 2016-08-04
EP2958889A1 (en) 2015-12-30
CA2902342A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
AU2014218598B2 (en) Neoseptins: small molecule adjuvants
TWI794629B (zh) Hiv抑制劑化合物
TWI583696B (zh) 樺腦（ｂｅｔｕｌｉｎ）衍生物
CN104321060B (zh) α-氨基硼酸衍生物，选择性免疫蛋白酶体抑制剂
JP7042804B2 (ja) ピペラジンカルバメート、及びその製造と使用の方法
AU2016374416A1 (en) Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
TW202102233A (zh) 用於hiv治療之化合物
WO2013058824A1 (en) Monomers capable of dimerizing in an aqueous solution, and methods of using same
CN112521386B (zh) 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途
JP2014523887A (ja) アミノプロパンジオール誘導体、準備、および医薬品組成物および用途
TW202615434A (zh) Nek7激酶抑制劑
TW434235B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
CA3026178C (en) Diprovocims: a new and potent class of tlr agonists
CA2957372C (en) Tlr-independent small molecule adjuvants
CN102491956B (zh) 左旋盐酸司他斯汀及其制备方法
KR20180054826A (ko) Hiv 성숙 억제 활성을 갖는 화합물
KR20210151068A (ko) 스핑고신 1 포스페이트 수용체 조절제
KR20210150371A (ko) 스핑고신 1 포스페이트 수용체 조절제
KR20220118267A (ko) Fxr 작용제로서 아자바이사이클로알킬 유도체 화합물 및 이의 용도
KR20180028534A (ko) Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
KR20180028535A (ko) Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
JP2002338469A (ja) Ｖｄａｃ機能阻害剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151027

MKLA Lapsed

Effective date: 20220225